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Background: To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination
(TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer.
Materials and methods: Previously untreated patients with metastatic colorectal cancer received
raltitrexed 3 mg/m2 plus oxaliplatin 100 mg/m2, both intravenously, on day 1 every 3 weeks. Patients
were re-evaluated after every third cycle and chemotherapy was continued up to tolerance or disease
progression.
Results: Fifty-eight patients from 13 Italian Group for the Study of Gastrointestinal Tract Carcinomas
(GISCAD) centers were accrued from September 1999 to November 2000. According to the intention-
to-treat analysis from 58 patients, the overall response rate was 50% [95% confidence interval (CI)
38% to 62%], with three complete responses and 26 partial responses. The median overall survival
(44 patients currently alive) was >9 months and the median time to disease progression was 6.5 months
(range 1–15 months). The main hematological toxicity was grade III/IV neutropenia, which occurred in
17% of patients, while anemia and thrombocytopenia were uncommon. Grade III/IV non-hematological
toxicities were transient transaminitis (17% of patients); asthenia (16% of patients); neurotoxicity
(10% of patients) and diarrhea (7% of patients). No toxic death was observed, one patient with grade IV
asthenia after the first cycle refused chemotherapy.
Conclusions: The results of this study suggest that the TOMOX combination is an effective and well
tolerated regimen for the treatment of advanced colorectal cancer. Its ease of administration and patient
tolerance warrant further investigation as an alternative to fluoropyrimidine-based regimens with
repeated and prolonged fluorouracil infusions.
Key words: chemotherapy, colorectal cancer, oxaliplatin, raltitrexed
Introduction
Over the last few decades, major improvements have been
achieved in the treatment of metastatic colorectal cancer; new
effective compounds and fluorouracil schedules have
produced better results than conventional fluorouracil-based
regimens [1]. The bimonthly combination of bolus plus con-
tinuous infusion of fluorouracil and folinic acid, known as the
‘de Gramont’ regimen, showed a higher response rate and
longer progression-free survival than the combination of the
same drugs in the monthly 5-days bolus North Central Cancer
Treatment Group/Mayo clinic regimen [2]. New cytotoxic
agents, such as the topoisomerase I inhibitor irinotecan [3], the
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platinum derivative oxaliplatin [4] or the novel thymidylate
synthase inhibitor raltitrexed [5, 6] demonstrated significant
single-agent activity in the setting of first- and second-line
chemotherapy. At present, the de Gramont regimen coupled
with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) can be
considered as two of the most effective combinations for the
treatment of advanced colorectal cancer [7, 8].
Ongoing clinical trials are investigating innovative chemo-
therapeutic strategies and combinations of new drugs. Chemo-
therapy with raltitrexed and oxaliplatin has the advantage of a
short infusion every 3 weeks, with potentially higher levels of
acceptability among patients than schedules with repeated and
prolonged fluorouracil infusions [4, 6]. Raltitrexed and oxali-
platin have different mechanisms of action, different toxicity
profiles and an additive effect in experimental studies. In two
randomized phase III studies, patients who received the com-
bination of oxalipatin, fluorouracil and leucovorin achieved
higher response rates and longer progression-free survival
than patients treated with fluorouracil/leucovorin [1, 8]. Ralti-
trexed was investigated in four randomized trials and com-
pared with fluorouracil-based chemotherapy [9–12]. Response
rates were similar between treatment arms, but one of these
studies showed a survival advantage in favor of patients
treated with conventional fluorouracil/leucovorin [9].
The raltitrexed–oxaliplatin combination has been explored
in phase I studies, both drugs were administered as short intra-
venous infusions every 3 weeks and recommended doses for
phase II studies resulted in the same doses as for single agent
use [13, 14]. In early phase II studies [14, 15], the combination
of raltitrexed 3 mg/m2 with oxaliplatin 130 mg/m2 showed
promising results, although oxalipaltin-related neurotoxicity
was one of the most common side effects, with an incidence in
patients ranging from 67% [14] to 97% [15].
We performed a multi-institutional phase II study of a ralti-
trexed/oxaliplatin combination (TOMOX) as first-line chemo-
therapy for patients with metastatic colorectal cancer. Given
the relationship between incidence of neurotoxicity and
cumulative oxaliplatin dose [4], we assessed the safety and
efficacy of a TOMOX combination with oxaliplatin 100 mg/m2
every 3 weeks.
Materials and methods
Patient selection
Chemotherapy-naïve patients with pathologically confirmed, relapsed or
metastatic colorectal cancer were considered eligible for the study. Other
eligibility criteria were bidimensionally measurable metastatic lesions,
Eastern Cooperative Oncology Group (ECOG) performance status 0–2;
age <75 years, and normal liver, renal and bone marrow functions. Careful
evaluation of renal function was performed before starting chemotherapy;
patients were excluded in the case of serum creatinine concentrations
>1.5 mg/dl and creatinine clearance <50 ml/min. If prior adjuvant chemo-
therapy had been given, it had to have been completed for at least
6 months. The protocol was approved by each local ethics committee and
all patients gave written informed consent. The primary endpoints were
the analysis of tumor response and toxicity. Secondary endpoints were
time to disease progression (TTP) and overall survival.
Treatment plan
Chemotherapy consisted of a 1 day every 3 weeks intravenous adminis-
tration of raltitrexed 3 mg/m2 (15-min infusion) followed by a 2-h infusion
of oxaliplatin 100 mg/m2. Full doses of both drugs were given if the
neutrophil count was ≥1.5 × 109/l and the platelet count ≥100 × 109/l. In
the case of grade III toxicity, dose reductions were not recommended and
patients necessitated a 7-day treatment delay. Patients were taken off
study if there was no complete recovery from toxicity within 3 weeks after
the last course. The doses of both drugs were reduced by 25% in the case
of grade IV toxicity. Patients with complete response (CR) or disease
progression did not receive further chemotherapy. Patients with partial
response (PR) or stable disease continued chemotherapy until progres-
sion, toxicity or refusal.
Evaluation procedures
Pretreatment evaluation consisted of baseline studies including medical
history, physical examination, blood chemistries, urinoanalysis, ECG and
carcinoembryonic antigen (CEA) serum levels. Also, chest X-rays,
abdominal computed tomography or magnetic resonance scan, bone scan
and any other test to identify the extent of disease were performed within
1 month before the onset of chemotherapy. Patients were re-evaluated
after every third treatment course and every 2 months after treatment
withdrawal. Complete blood cell counts and serum chemistries for
monitoring liver and renal functions were performed weekly during treat-
ment and before every course. The study was monitored by the GISCAD
Data and Safety Monitoring Committee and an internal panel evaluated
tumor response according to World Health Organization criteria [16]. The
National Cancer Institute/Common Toxicity Criteria (NCI/CTC) version
2.0 [17] were used to evaluate treatment-related side effects.
Statistical plan
A two-staged Simon accrual design was adopted for this phase II trial. The
minimum target activity level was 20% and early discontinuation of the
study was planned in the case of no response in the first 12 assessable
patients. Alternatively, a planned sample size of 55 evaluable patients was
chosen to better estimate efficacy; 25% maximum width of the 95%
confidence interval (CI) for an expected 40% overall response rate. TTP
was measured from the date of registration to the date of documented pro-
gressive disease or death. Overall survival was measured from the time of
registration to the date of death resulting from any cause.
Results
The study population consisted of 58 patients enrolled from
September 1999 to November 2000 from 13 participating
GISCAD centers. Synchronous metastatic disease was
observed in 27 patients. In 31 patients, metastatic colorectal
cancer was diagnosed during follow-up and the median time
to relapse from surgery was 13 months (range 2–96 months).
The clinico-pathological features of the enrolled patients are
summarized in Table 1. On the whole, 288 courses of chemo-
therapy were administered; five patients received less than
three cycles, 23 patients three to four cycles, 24 patients six
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to seven cycles and six patients nine to 10 cycles. For the
intention-to-treat analysis, all 58 patients were evaluated for
efficacy and toxicity.
Efficacy
Early discontinuation of treatment before the first evaluation
was caused by early progression (two patients), refusal for
personal reasons (two patients) and refusal due to grade IV
asthenia (one patient). Objective responses were achieved as
follows: 20 patients with PR after three cycles; six patients
with PR and two patients with CR after six cycles; one patient
with CR after nine cycles (previous stable disease). The median
time to response was 1.9 months (range 1.5–6 months).
According to the intention-to-treat analysis in the 58 patients,
the best overall response rate was 50% (95% CI 38% to 62%),
with three CRs, 26 PRs, 13 stable diseases and 16 failures.
Of the three patients who achieved CR, two had multiple
liver metastases and one patient had bilateral lung metastases.
Follow-up and survival
At the time of the last analysis (May 2001), the median follow-
up duration was 12 months (range 6–18 months), 44 patients
were alive (75%) and 14 patients had died due to progressive
disease. The median survival duration had not yet been
reached [>9 months (range 2–22+)], and the median time to
disease progression was 6.5 months (range 1–15 months).
Second-line chemotherapy was administered to 30 patients;
this consisted of CPT-11 plus fluorouracil in 28 patients and
prolonged infusional fluorouracil in two patients. Two patients
with PR and metastatic disease confined to the liver under-
went thermoablative treatment or chemo-embolization for
residual disease.
Toxicity
Toxicity data for the 58 patients are summarized in Table 2.
Neutropenia was the most common hematological toxicity to
occur: grade I/II in 52% of patients and grade III in 10% of
patients. No episodes of grade IV neutropenia were reported
and the median nadir of neutrophil counts was 1890/mm3
(range 550–5400/mm3). Transient transaminitis, nausea/vomit-
ing, asthenia and neurotoxicity were the most common non-
hematological side effects. Transient grade I–II transaminitis
was observed in 61% of patients and grade III/IV in 17% of
patients. The elevation of liver enzymes was asymptomatic
and it resolved after 1- or 2-week treatment delays. Grade III/
IV asthenia, diarrhea and nausea/vomiting were observed in
16%, 7% and 5% of patients, respectively. One patient, who
experienced grade IV asthenia, refused further chemotherapy.
Neurotoxicity was observed in 53% of patients and achieved
grade III after 12 cycles delivered to six patients (10%). Minor
toxicities were grade I alopecia in eight patients, grade I
myalgia in four patients, grade I dermatitis in two patients and
grade I renal toxicity in one patient.
According to the treatment plan, chemotherapy was delayed
at least once for 20 of the patients for a maximum of 14 days.
Treatment delays occurred more frequently after the third
cycle of chemotherapy because of grade III neutropenia,
transaminitis or asthenia. Three patients had a 25% dose
reduction of both cytotoxic because of severe (grade IV)
transaminitis or diarrhea. Neither allergic reactions nor drug-
related toxic death were observed.
Discussion
Over recent decades, the results of fluorouracil-based chemo-
therapy for metastatic colorectal cancer have slowly improved,
but the pace has quickened in recent years. Innovative fluoro-
uracil schedules and new active compounds have allowed
medical oncologists to offer patients first- and second-line
treatments giving a higher chance of objective response and
longer survival times than in the past [1].
Table 1. Characteristics of the 58 patients enrolled in the study
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology 
Group; FU/LV, fluorouracil/leucovorin; UNL, upper normal limit.
No. of patients 58
Sex ratio
Male 31
Female 27
Median age (range) 61 years (45–70)
ECOG performance status
0 31
1 26
2 1
Prior adjuvant therapy
None 27
FU/LV 31
Number of organs involved
1 33
2 13
>3 12
Sites of metastases
Liver 45
Lung 30
Other 23
CEA level
<10 ng/ml 20
≥10 ng/ml 38
Alkaline phosphatases >UNL 22
Lactate dehydrogenase >UNL 30
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In the present study, the combination of raltitrexed and
oxaliplatin showed activity with good patient tolerance. So
far, two previous studies have analyzed the toxicity and effi-
cacy of this regimen. Scheithauer et al. [14] treated 42 patients
in the phase II portion of their study, employing raltitrexed
3 mg/m2 (15 min infusion) followed by a 2-h infusion of oxali-
platin 130 mg/m2, both intravenously every 3 weeks. The
intention-to-treat overall response rate was 47% (95% CI 32%
to 63%), the median progression-free survival was 9 months
and the median overall survival was >14.5 months (67% of
patients still alive at the time of analysis). Grade III–IV
neutropenia was the most common hematological toxicity
(21% of patients); transient transaminitis, peripheral neuro-
pathy and diarrhea were the most frequent non-hematological
side effects. The same treatment schedule was used by Douil-
lard et al. [15], who found in 63 patients an intention-to-treat
overall response rate of 57% (95% CI 46% to 69%) and a
median time to progression of 6.3 months. Safety data in
277 cycles (66 patients) confirmed neutropenia (grade III–IV
in 16% of patients) and neurotoxicity (grade I–II in 97% of
patients) as two of the most common side effects of the ralti-
trexed/oxaliplatin combination; two treatment-related deaths
were observed.
Comparison of results between phase II trials is unfeasible;
however, it seems that the TOMOX combination with oxali-
platin 100 mg/m2 has a similar efficacy to that observed in
patients treated with oxaliplatin 130 mg/m2 [14, 15]. No unex-
pected severe adverse effects were observed in this trial and
the toxicity profile of the TOMOX regimen parallels the clin-
ical experiences with single-agent raltitrexed [18] and oxali-
platin [4]. Most likely, the strict inclusion criteria, the careful
baseline evaluation of patients and their characteristics, and
the appropriate treatment delays and/or dose reductions
avoided life-threatening toxicities [18]. Also, the oxaliplatin
100 mg/m2 dose may explain the low incidence of neuro-
toxicity. In the present study, 24 patients received six to seven
TOMOX cycles and six patients received nine to 10 cycles. It
was found that the risk of neurotoxicity increases with cumula-
tive oxaliplatin dose [19]; for instance, oxaliplatin cumulative
doses of 780 mg/m2 and 1170 mg/m2 correlated with an
incidence of neurotoxicity of 10% and 50%, respectively.
Combination chemotherapy with oxaliplatin at the maximum
tolerated dose may not offer higher efficacy, and conversely,
it may increase the incidence of neurotoxicity, which is
reversible but dependent on the cumulative dose [19].
There is an increasing need to assess the impact of colo-
rectal cancer therapies on the patients’ quality of life [20–22].
Based on administration and/or side-effect attributes, Young
et al. [20] compared raltitrexed and bolus or infusional
5-fluorouracil regimens in advanced colorectal cancer. On the
basis of similar palliative effects, patients preferred raltitrexed
over other regimens, and they ranked it more acceptable than
the Mayo, de Gramont or Lokich regimens. These results are
in contrast to that reported by Maughan et al. [12], who found
an unexpectedly high incidence of treatment-related deaths
(4% of patients) and a worse quality of life in patients treated
with raltitrexed than patients treated with the de Gramont or
Lokich regimens. Raltitrexed-based chemotherapy may repre-
sent a valid treatment option that offers the opportunity of
improving acceptability of chemotherapy to patients; how-
ever, these data suggest the necessity of performing further
assessments of toxicity and quality-of-life issues.
The TOMOX combination warrants evaluation of costs in
comparison with other chemotherapeutic regimens. In two
retrospective economic analyses, raltitrexed showed substan-
tial equivalence of cost with the Mayo regimen [23], while it
was less expensive than the de Gramont regimen [24]. Future
clinical trials should consider economic evaluations and should
clarify whether the high cost of chemotherapy drugs with the
raltitrexed/oxaliplatin combination may be counterbalanced
by lower demands on clinic and pharmacy resources.
In conclusion, the results of the present study and data from
ongoing investigations provide evidence that the TOMOX
regimen has good efficacy and moderate toxicity as first-line
Table 2. Side effects reported in the 58 enrolled patients (National Cancer Institute/Common Toxicity 
Criteria)
Toxicity Number of patients with toxicity (%)
Grade 1 Grade 2 Grade 3 Grade 4 All grades
Transaminitis 20 (34) 16 (27) 9 (15) 1 (2) 46 (78)
Neutropenia 19 (32) 12 (20) 6 (10) 0 37 (62)
Nausea/vomiting 21 (36) 10 (17) 4 (5) 0 35 (58)
Asthenia 13 (22) 9 (15) 8 (14) 1 (2) 31 (53)
Neuropathy 17 (29) 8 (14) 6 (10) 0 31 (53)
Diarrhea 16 (27) 2 (3) 3 (4) 2 (3) 23 (37)
Anemia 17 (29) 4 (5) 1 (2) 0 22 (36)
Mucositis 5 (8) 6 (10) 1 (2) 0 12 (20)
Thrombocytopenia 8 (14) 2 (3) 0 0 10 (17)
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chemotherapy for metastatic colorectal cancer. Most prob-
ably, the favorable characteristics of the majority of enrolled
patients (median age 61 years, ECOG performance status 0–1,
one or two organs involved, normal alkaline phosphatase and
LDH values) contributed to the positive treatment results and
avoided significant toxicity. For this reason, the results of this
early phase II study should be looked at with caution and
replicated in phase III trials. The TOMOX chemotherapy
should be compared for efficacy, safety, quality of life and
costs to the FOLFOX and FOLFIRI regimens in a prospective
randomized trial.
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